Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 18/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 18/20 | 1.00 |
| ▸ | KDR | P35968 | 16/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.74 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906755 | 0.97 | EPHB4 (0.94) | EPHB4EPHA2KDRERBB2 | |
| SCHEMBL906917 | 0.94 | EPHB4 (0.88) | EPHB4EPHA2KDRERBB2EGFR | |
| SCHEMBL909069 | 0.92 | EPHB4 (1.00) | EPHB4EPHA2KDRERBB2EGFR | |
| SCHEMBL907009 | 0.87 | EPHB4 (1.00) | EPHB4EPHA2KDRERBB2EGFR | |
| SCHEMBL907004 | 0.85 | EPHB4 (1.00) | EPHB4EPHA2KDRERBB2EGFR | |
| SCHEMBL17735585 | 0.85 | EPHA2 (1.00) | EPHB4EPHA2KDRERBB2EGFR | |
| SCHEMBL906836 | 0.85 | EPHA2 (1.00) | EPHB4EPHA2KDRERBB2EGFR | |
| SCHEMBL907593 | 0.83 | EPHB4 (0.85) | EPHB4EPHA2KDRERBB2EGFR | |
| SCHEMBL907276 | 0.82 | EPHA2 (1.00) | EPHB4EPHA2KDRERBB2 | |
| SCHEMBL910069 | 0.82 | EPHA2 (1.00) | EPHB4EPHA2KDRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2006-03-30 | — | — | US | claimed |
| US-10266518-B2 | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof | SYMPHONY EVOLUTION, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266518-B2 | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof | SYMPHONY EVOLUTION, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | SYMPHONY EVOLUTION, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | SYMPHONY EVOLUTION, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | SYMPHONY EVOLUTION, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-9796704-B2 | Substituted quinazolines as receptor-type kinase inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796704-B2 | Substituted quinazolines as receptor-type kinase inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796704-B2 | Substituted quinazolines as receptor-type kinase inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2277867-A2 | Compounds, pharmaceutical compositions thereof and their use in treating cancer | Symphony Evolution, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | EXELIXIS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20090318373-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-12-24 | — | — | US | disclosed |
| US-20090318373-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-12-24 | — | — | US | disclosed |
| US-20090318373-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-12-24 | — | — | US | disclosed |
| US-7576074-B2 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-08-18 | — | — | US | disclosed |
| US-7576074-B2 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-08-18 | — | — | US | disclosed |
| US-7576074-B2 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-08-18 | — | — | US | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | EGFR, EPHA2, ERBB4 | EPHB4 16/4885EPHA2 2/4885KDR 17/4885 |
| US-10266518-B2 | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof | EGFR, ERBB4, ERBB3 | EPHB4 17/4885EPHA2 4/4885KDR 16/4885 |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | EGFR, EPHA2, ERBB4 | EPHB4 16/4885EPHA2 2/4885KDR 17/4885 |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | TP53, PHKG1, TNNI3K | EPHB4 2878/4885EPHA2 2745/4885KDR 2390/4885 |
| US-20090318373-A1 | Receptor-type kinase modulators and methods of use | EGFR, EPHA2, ERBB4 | EPHB4 16/4885EPHA2 2/4885KDR 17/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | EPHB4 1441/4885EPHA2 977/4885KDR 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.